Bright Health Group Reports First Quarter 2023 Results
-
Q1’23 Revenue from Continuing Business of
$756.3 million 23% year over year on strong growth in Consumer Care external value-based consumers served -
Q1’23 Net Loss from Continuing Business of
$94.8 million $35.1 million - Consumer Care segment generated positive Operating Income in Q1’23
-
Q1’23 California MCR was
89.0% excluding prior period Medical Costs, consistent with seasonal expectations - Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability†
“Bright Health had a strong start to the year in the First Quarter. The Consumer Care segment generated positive Operating Income, and the Medical Cost Ratio in our Medicare Advantage business was in-line with our expectations after adjusting for prior period costs and given normal seasonality patterns,” said Mike Mikan, President and CEO of Bright Health. “Our Consumer Care business continued to add value-based care consumers in the First Quarter, and along with strength in our REACH ACO business, we believe that the segment is positioned well for long-term profitable growth.”
Key Metrics
|
As of March 31, |
||
|
2023 |
|
2022 |
Consumer and Patient Metrics |
|
|
|
Bright HealthCare Consumers |
123,000 |
|
120,000 |
Consumer Care Value-Based Consumers |
373,000 |
|
530,000 |
|
Three Months Ended |
||||||
($ in thousands) |
March 31 |
||||||
|
|
2023 |
|
|
|
2022 |
|
Financial Metrics |
|
|
|
||||
Revenue |
$ |
756,341 |
|
|
$ |
613,263 |
|
Medical Cost Ratio - Bright HealthCare1 |
|
95.0 |
% |
|
|
96.7 |
% |
Net Loss from Continuing Operations |
$ |
(94,792 |
) |
|
$ |
(163,514 |
) |
Adjusted EBITDA (non-GAAP) |
$ |
(35,053 |
) |
|
$ |
(59,089 |
) |
1 Bright HealthCare Medical Cost Ratio includes |
|||||||
See the table at the end of this release for additional information and a reconciliation of the non-GAAP measures used in the table above. |
|||||||
Financial Outlook
For full year 2023, Bright Health is providing the following guidance and commentary:
Bright Health’s 2023 Revenue and Adjusted EBITDA profitability expectations are unchanged, while Adjusted Operating Cost Ratio now forecast for the high end of the prior range.
-
Bright Health’s Enterprise Revenue is expected to be between
$2.9 billion $3.1 billion -
On a segment basis, Bright HealthCare Revenue is expected to be greater than
$1.8 billion $1.1 billion $1.3 billion -
Enterprise Adjusted Operating Cost Ratio is expected to be approximately
14% † - Bright Health expects to be Adjusted EBITDA profitable in 2023†
† Reconciliations of projected Adjusted EBITDA and projected Adjusted Operating Cost Ratio to the most directly comparable GAAP financial measures are not provided because the Company is unable to provide such reconciliations without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact and the periods in which the non-GAAP adjustments may be recognized. With respect to Adjusted EBITDA, these GAAP measures may include the impact of such items as interest expense, income tax expense, depreciation and amortization, impairment of goodwill or intangible assets, transaction costs, share-based compensation expense, changes in the fair value of equity securities, changes in the fair value of contingent consideration, contract termination costs, restructuring costs; and the tax effect of all such items. Historically, the Company has excluded these items from non-GAAP financial measures. With respect to Adjusted Operating Cost Ratio, these GAAP measures may include the impact of such items as stock-based compensation, changes in the fair value of contingent consideration, contract termination costs, and depreciation and amortization. The Company currently expects to continue to exclude these items in future disclosures of non-GAAP financial measures and may also exclude other items that may arise (collectively, “non-GAAP adjustments”). The decisions and events that typically lead to the recognition of non-GAAP adjustments, such as a decision to exit part of the business, are inherently unpredictable as to if or when they may occur. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Earnings Conference Call
As previously announced, Bright Health Group will discuss the Company’s results, strategy, and outlook on a conference call with investors at 8:00 a.m. Eastern Time today. Bright Health Group will host a live webcast of this conference call which can be accessed from the Investor Relations page of the company’s website (investors.brighthealthgroup.com). Following the call, a webcast replay will be available on the same site. This earnings release and the Form 8-K filed May 9, 2023 can be accessed on the Investor Relations page of the Company’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases,
About Bright Health Group
Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in
Forward-Looking Statements
Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans and expectations with respect to Bright Health Group, Inc. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; our ability to comply with the terms of our credit facility, including financial covenants, both during and after any waiver period, and/or obtain any additional waivers of any terms of our credit facility to the extent required; our ability to sell our Medicare Advantage business in
Bright Health Group, Inc. and Subsidiaries Consolidated Balance Sheets (in thousands, except share and per share data) (Unaudited) |
|||||||
|
March 31,
|
|
December 31,
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
382,506 |
|
|
$ |
466,325 |
|
Short-term investments |
|
12,112 |
|
|
|
13,206 |
|
Accounts receivable, net of allowance of |
|
125,241 |
|
|
|
73,605 |
|
ACO REACH performance year receivable |
|
882,884 |
|
|
|
99,181 |
|
Current assets of discontinued operations |
|
2,225,739 |
|
|
|
2,783,474 |
|
Prepaids and other current assets |
|
142,932 |
|
|
|
134,843 |
|
Total current assets |
|
3,771,414 |
|
|
|
3,570,634 |
|
Other assets: |
|
|
|
||||
Long-term investments |
|
3,816 |
|
|
|
5,401 |
|
Property, equipment and capitalized software, net |
|
40,747 |
|
|
|
42,596 |
|
Goodwill |
|
760,078 |
|
|
|
760,078 |
|
Intangible assets, net |
|
242,286 |
|
|
|
249,083 |
|
Other non-current assets |
|
29,664 |
|
|
|
37,260 |
|
Total other assets |
|
1,076,591 |
|
|
|
1,094,418 |
|
Total assets |
|
4,848,005 |
|
|
|
4,665,052 |
|
Liabilities, Redeemable Noncontrolling Interest, Redeemable Preferred Stock and Shareholders’ Equity (Deficit) |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Medical costs payable |
$ |
458,465 |
|
|
$ |
411,753 |
|
Accounts payable |
|
33,638 |
|
|
|
67,854 |
|
Unearned revenue |
|
139,416 |
|
|
|
242 |
|
ACO REACH performance year obligation |
|
719,420 |
|
|
|
— |
|
Short-term borrowings |
|
303,947 |
|
|
|
303,947 |
|
Current liabilities of discontinued operations |
|
2,225,739 |
|
|
|
2,783,474 |
|
Other current liabilities |
|
131,256 |
|
|
|
121,424 |
|
Total current liabilities |
|
4,011,881 |
|
|
|
3,688,694 |
|
Other liabilities |
|
32,191 |
|
|
|
36,673 |
|
Total liabilities |
|
4,044,072 |
|
|
|
3,725,367 |
|
|
|
|
|
||||
Redeemable noncontrolling interests |
|
223,503 |
|
|
|
219,758 |
|
Redeemable Series A preferred stock, |
|
747,481 |
|
|
|
747,481 |
|
Redeemable Series B preferred stock, |
|
172,936 |
|
|
|
172,936 |
|
Shareholders’ equity (deficit): |
|
|
|
||||
Common stock, |
|
63 |
|
|
|
63 |
|
Additional paid-in capital |
|
3,005,592 |
|
|
|
2,972,271 |
|
Accumulated deficit |
|
(3,331,406 |
) |
|
|
(3,156,395 |
) |
Accumulated other comprehensive loss |
|
(2,236 |
) |
|
|
(4,429 |
) |
Treasury Stock, at cost, 2,522,148 shares at March 31, 2023, and December 31, 2022, respectively |
|
(12,000 |
) |
|
|
(12,000 |
) |
Total shareholders’ equity (deficit) |
|
(339,987 |
) |
|
|
(200,490 |
) |
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit) |
$ |
4,848,005 |
|
|
$ |
4,665,052 |
|
Bright Health Group, Inc. and Subsidiaries Consolidated Statements of Income (Loss) (in thousands, except share and per share data) (Unaudited) |
|||||||
|
Three Months Ended March 31, |
||||||
|
|
2023 |
|
|
|
2022 |
|
Revenue: |
|
|
|
||||
Premium revenue |
$ |
502,918 |
|
|
$ |
458,962 |
|
ACO REACH revenue |
|
239,807 |
|
|
|
182,797 |
|
Service revenue |
|
13,570 |
|
|
|
12,392 |
|
Investment income (loss) |
|
46 |
|
|
|
(40,888 |
) |
Total revenue |
|
756,341 |
|
|
|
613,263 |
|
Operating expenses: |
|
|
|
||||
Medical costs |
|
688,515 |
|
|
|
594,248 |
|
Operating costs |
|
140,324 |
|
|
|
159,117 |
|
Restructuring charges |
|
3,357 |
|
|
|
6,864 |
|
Depreciation and amortization |
|
9,891 |
|
|
|
12,897 |
|
Total operating expenses |
|
842,087 |
|
|
|
773,126 |
|
Operating loss |
|
(85,746 |
) |
|
|
(159,863 |
) |
Interest expense |
|
7,787 |
|
|
|
1,193 |
|
Other income |
|
— |
|
|
|
(784 |
) |
Loss from continuing operations before income taxes |
|
(93,533 |
) |
|
|
(160,272 |
) |
Income tax expense |
|
1,259 |
|
|
|
3,242 |
|
Net loss from continuing operations |
|
(94,792 |
) |
|
|
(163,514 |
) |
Loss from discontinued operations, net of tax |
|
(74,669 |
) |
|
|
(17,115 |
) |
Net Loss |
|
(169,461 |
) |
|
|
(180,629 |
) |
Net earnings from continuing operations attributable to noncontrolling interests |
|
(5,550 |
) |
|
|
(14,605 |
) |
Series A preferred stock dividend accrued |
|
(9,714 |
) |
|
|
(8,938 |
) |
Series B preferred stock dividend accrued |
|
(2,180 |
) |
|
|
— |
|
Net loss attributable to Bright Health Group, Inc. common shareholders |
$ |
(186,905 |
) |
|
$ |
(204,172 |
) |
|
|
|
|
||||
Basic and diluted loss per share attributable to Bright Health Group, Inc. common shareholders |
|
|
|
||||
Continuing operations |
$ |
(0.18 |
) |
|
$ |
(0.30 |
) |
Discontinued operations |
|
(0.12 |
) |
|
|
(0.02 |
) |
Basic and diluted loss per share |
|
(0.30 |
) |
|
|
(0.32 |
) |
|
|
|
|
||||
Basic and diluted weighted-average common shares outstanding |
|
631,534 |
|
|
|
628,765 |
|
Bright Health Group, Inc. and Subsidiaries Consolidated Statements of Cash Flows (in thousands) (Unaudited) |
|||||||
|
Three Months Ended March 31, |
||||||
|
|
2023 |
|
|
|
2022 |
|
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(169,461 |
) |
|
$ |
(180,629 |
) |
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
9,891 |
|
|
|
13,041 |
|
Impairment of intangible assets |
|
— |
|
|
|
6,720 |
|
Share-based compensation |
|
33,320 |
|
|
|
32,921 |
|
Deferred income taxes |
|
436 |
|
|
|
717 |
|
Unrealized loss on equity securities |
|
— |
|
|
|
40,968 |
|
Other, net |
|
(2,807 |
) |
|
|
2,378 |
|
Changes in assets and liabilities, net of acquired assets and liabilities: |
|
|
|
||||
Accounts receivable |
|
(43,409 |
) |
|
|
(29,221 |
) |
ACO REACH performance year receivable |
|
(783,703 |
) |
|
|
(638,641 |
) |
Other assets |
|
22,448 |
|
|
|
(22,270 |
) |
Medical cost payable |
|
(423,459 |
) |
|
|
337,180 |
|
Risk adjustment payable |
|
4,153 |
|
|
|
354,276 |
|
Accounts payable and other liabilities |
|
(119,416 |
) |
|
|
52,182 |
|
Unearned revenue |
|
137,563 |
|
|
|
(18,402 |
) |
ACO REACH performance year obligation |
|
719,420 |
|
|
|
533,537 |
|
Net cash (used in) provided by operating activities |
|
(615,024 |
) |
|
|
484,757 |
|
Cash flows from investing activities: |
|
|
|
||||
Purchases of investments |
|
(2,880 |
) |
|
|
(782,091 |
) |
Proceeds from sales, paydown, and maturities of investments |
|
690,161 |
|
|
|
154,765 |
|
Purchases of property and equipment |
|
(1,863 |
) |
|
|
(5,491 |
) |
Business divestitures, net of cash disposed of |
|
1,370 |
|
|
|
||
Business acquisitions, net of cash acquired |
|
— |
|
|
|
(310 |
) |
Net cash provided by (used in) investing activities |
|
686,788 |
|
|
|
(633,127 |
) |
Cash flows from financing activities: |
|
|
|
||||
Net proceeds from short-term borrowings |
|
— |
|
|
|
(155,000 |
) |
Proceeds from issuance of preferred stock |
|
— |
|
|
|
747,481 |
|
Proceeds from issuance of common stock |
|
1 |
|
|
|
257 |
|
Distributions to noncontrolling interest holders |
|
(1,805 |
) |
|
|
— |
|
Net cash (used in) provided by financing activities |
|
(1,804 |
) |
|
|
592,738 |
|
Net increase in cash and cash equivalents |
|
69,960 |
|
|
|
444,368 |
|
Cash and cash equivalents – beginning of year |
|
1,932,290 |
|
|
|
1,061,179 |
|
Cash and cash equivalents – end of period |
$ |
2,002,250 |
|
|
$ |
1,505,547 |
|
Supplemental disclosures of cash flow information: |
|
|
|
||||
Changes in unrealized loss on available-for-sale securities in OCI |
$ |
2,193 |
|
|
$ |
(26,340 |
) |
Cash paid for interest |
|
7,157 |
|
|
|
1,168 |
|
Bright Health Group, Inc. and Subsidiaries Segment Information (in thousands) (Unaudited) |
|||||||
Bright HealthCare |
|
|
|
||||
($ in thousands) |
Three Months Ended
|
||||||
Statement of income (loss) and operating data: |
|
2023 |
|
|
|
2022 |
|
|
|
|
|
||||
Revenue: |
|
|
|
||||
Premium revenue |
$ |
453,370 |
|
|
$ |
430,313 |
|
Investment income (loss) |
|
46 |
|
|
|
80 |
|
Total revenue |
|
453,416 |
|
|
|
430,393 |
|
Operating expenses |
|
|
|
||||
Medical costs |
|
430,928 |
|
|
|
416,200 |
|
Operating costs |
|
49,453 |
|
|
|
41,117 |
|
Depreciation and amortization |
|
4,408 |
|
|
|
4,459 |
|
Total operating expenses |
|
484,789 |
|
|
|
461,776 |
|
Operating loss |
$ |
(31,373 |
) |
|
$ |
(31,383 |
) |
Medical Cost Ratio (MCR)(1) |
|
95.0 |
% |
|
|
96.7 |
% |
(1) Bright HealthCare medical cost ratio includes |
|||||||
Consumer Care |
|
|
|
|||
($ in thousands) |
Three Months Ended
|
|||||
Statement of income (loss) and operating data: |
2023 |
|
|
2022 |
|
|
|
|
|
|
|||
Revenue: |
|
|
|
|||
Premium revenue |
$ |
49,548 |
|
$ |
28,649 |
|
Affiliated revenue |
|
— |
|
|
368,053 |
|
ACO REACH revenue |
|
239,807 |
|
|
182,797 |
|
Service revenue |
|
13,570 |
|
|
12,392 |
|
Investment income (loss) |
|
— |
|
|
(40,968 |
) |
Total revenue |
|
302,925 |
|
|
550,923 |
|
Operating expenses |
|
|
|
|||
Medical costs |
|
257,587 |
|
|
566,694 |
|
Operating costs |
|
37,814 |
|
|
47,281 |
|
Depreciation and amortization |
|
3,132 |
|
|
7,002 |
|
Total operating expenses |
|
298,533 |
|
|
620,977 |
|
Operating income (loss) |
$ |
4,392 |
|
$ |
(70,054 |
) |
Bright Health Group, Inc. and Subsidiaries Historical Financials Recast Income Statement(1) (in thousands) |
|||||||||||||||
($ in thousands) |
|
||||||||||||||
|
Three Months Ended |
||||||||||||||
Consolidated Statements of Income (loss) and operating data: |
March 31, |
|
June 30, |
|
September 30, |
|
December 31, |
||||||||
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
458,962 |
|
|
$ |
437,234 |
|
|
$ |
423,995 |
|
|
$ |
444,758 |
|
ACO REACH revenue |
|
182,797 |
|
|
|
137,205 |
|
|
|
145,433 |
|
|
|
188,652 |
|
Service revenue |
|
12,392 |
|
|
|
12,811 |
|
|
|
12,079 |
|
|
|
10,731 |
|
Investment income (loss) |
|
(40,888 |
) |
|
|
(16,213 |
) |
|
|
4,882 |
|
|
|
(2,800 |
) |
Total revenue |
|
613,263 |
|
|
|
571,037 |
|
|
|
586,389 |
|
|
|
641,341 |
|
Operating costs |
|
|
|
|
|
|
|
||||||||
Medical costs |
|
594,248 |
|
|
|
507,322 |
|
|
|
506,235 |
|
|
|
598,438 |
|
Operating costs |
|
159,117 |
|
|
|
140,650 |
|
|
|
146,532 |
|
|
|
185,731 |
|
Restructuring charges |
|
6,864 |
|
|
|
2,791 |
|
|
|
1,215 |
|
|
|
20,869 |
|
Goodwill impairment |
|
— |
|
|
|
— |
|
|
|
70,017 |
|
|
|
1,208 |
|
Intangibles impairment |
|
— |
|
|
|
— |
|
|
|
42,611 |
|
|
|
— |
|
Depreciation and amortization |
|
12,897 |
|
|
|
13,227 |
|
|
|
13,904 |
|
|
|
10,402 |
|
Total operating costs |
|
773,126 |
|
|
|
663,990 |
|
|
|
780,514 |
|
|
|
816,648 |
|
Operating loss |
|
(159,863 |
) |
|
|
(92,953 |
) |
|
|
(194,125 |
) |
|
|
(175,307 |
) |
Interest expense |
|
1,193 |
|
|
|
337 |
|
|
|
4,905 |
|
|
|
6,386 |
|
Other income |
|
(784 |
) |
|
|
2 |
|
|
|
(2 |
) |
|
|
— |
|
Loss from continuing operations before income taxes |
|
(160,272 |
) |
|
|
(93,292 |
) |
|
|
(199,028 |
) |
|
|
(181,693 |
) |
Income tax expense (benefit) |
|
3,242 |
|
|
|
2,904 |
|
|
|
1,762 |
|
|
|
(4,228 |
) |
Net loss from continuing operations |
|
(163,514 |
) |
|
|
(96,196 |
) |
|
|
(200,790 |
) |
|
|
(177,465 |
) |
Loss from discontinued operations, net of tax |
|
(17,115 |
) |
|
|
(155,134 |
) |
|
|
(69,339 |
) |
|
|
(480,327 |
) |
Net loss |
|
(180,629 |
) |
|
|
(251,330 |
) |
|
|
(270,129 |
) |
|
|
(657,792 |
) |
Net earnings from continuing operations attributable to noncontrolling interests |
|
(14,605 |
) |
|
|
(23,336 |
) |
|
|
(46,711 |
) |
|
|
(11,012 |
) |
Series A preferred stock dividend accrued |
|
(8,938 |
) |
|
|
(9,461 |
) |
|
|
(9,684 |
) |
|
|
(9,806 |
) |
Series B preferred stock dividend accrued |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,798 |
) |
Net loss attributable to Bright Health Group, Inc. common shareholders |
$ |
(204,172 |
) |
|
$ |
(284,127 |
) |
|
$ |
(326,524 |
) |
|
$ |
(680,408 |
) |
Operating Cost Ratio |
|
25.9 |
% |
|
|
24.6 |
% |
|
|
25.0 |
% |
|
|
29.0 |
% |
(1)The 2022 quarterly Statements of Income (Loss) have been recast to reflect the move of the IFP business to discontinued operations as well as to correct the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements and an error identified in the data to account for our risk adjustment factor. |
|||||||||||||||
Bright Health Group, Inc. and Subsidiaries Historical Financials Recast Segment Information (1) (in thousands) (Unaudited) |
|||||||||||||||
Bright HealthCare |
Recast 2022 Segment Information |
||||||||||||||
($ in thousands) |
|
|
|
|
|
||||||||||
|
Three Months Ended |
||||||||||||||
|
March 31, |
|
June 30, |
|
September 30, |
|
December 31, |
||||||||
Statement of income (loss) and operating data: |
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
430,313 |
|
|
$ |
419,594 |
|
|
$ |
390,989 |
|
|
$ |
411,149 |
|
Investment income (loss) |
|
80 |
|
|
|
(29 |
) |
|
|
36 |
|
|
|
323 |
|
Total revenue |
|
430,393 |
|
|
|
419,565 |
|
|
|
391,025 |
|
|
|
411,472 |
|
Operating expenses |
|
|
|
|
|
|
|
||||||||
Medical costs |
|
416,200 |
|
|
|
378,801 |
|
|
|
355,347 |
|
|
|
400,586 |
|
Operating costs |
|
41,117 |
|
|
|
43,513 |
|
|
|
43,291 |
|
|
|
59,715 |
|
Goodwill impairment |
|
— |
|
|
|
— |
|
|
|
70,017 |
|
|
|
— |
|
Depreciation and amortization |
|
4,459 |
|
|
|
4,416 |
|
|
|
4,416 |
|
|
|
4,411 |
|
Total operating expenses |
|
461,776 |
|
|
|
426,730 |
|
|
|
473,071 |
|
|
|
464,712 |
|
Operating loss |
$ |
(31,383 |
) |
|
$ |
(7,165 |
) |
|
$ |
(82,046 |
) |
|
$ |
(53,240 |
) |
Medical Cost Ratio (MCR) |
|
96.7 |
% |
|
|
90.3 |
% |
|
|
90.9 |
% |
|
|
97.4 |
% |
Consumer Care |
Recast 2022 Segment Information |
||||||||||||||
($ in thousands) |
|
|
|
|
|
|
|
||||||||
|
Three Months Ended |
||||||||||||||
|
March 31, |
|
June 30, |
|
September 30, |
|
December 31, |
||||||||
Statement of income (loss) and operating data: |
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
||||||||
Revenue: |
|
|
|
|
|
|
|
||||||||
Premium revenue |
$ |
28,649 |
|
|
$ |
17,640 |
|
|
$ |
33,006 |
|
|
$ |
33,609 |
|
Affiliated revenue |
|
368,053 |
|
|
|
203,965 |
|
|
|
250,594 |
|
|
|
206,421 |
|
ACO REACH revenue |
|
182,797 |
|
|
|
137,205 |
|
|
|
145,433 |
|
|
|
188,652 |
|
Service revenue |
|
12,392 |
|
|
|
12,811 |
|
|
|
12,079 |
|
|
|
10,731 |
|
Investment income (loss) |
|
(40,968 |
) |
|
|
(16,184 |
) |
|
|
4,846 |
|
|
|
(3,123 |
) |
Total revenue |
|
550,923 |
|
|
|
355,437 |
|
|
|
445,958 |
|
|
|
436,290 |
|
Operating expenses |
|
|
|
|
|
|
|
||||||||
Medical costs |
|
566,694 |
|
|
|
326,532 |
|
|
|
403,069 |
|
|
|
548,283 |
|
Operating costs |
|
47,281 |
|
|
|
40,320 |
|
|
|
46,302 |
|
|
|
57,799 |
|
Goodwill impairment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,208 |
|
Intangible assets impairment |
|
— |
|
|
|
— |
|
|
|
42,611 |
|
|
|
— |
|
Depreciation and amortization |
|
7,002 |
|
|
|
7,195 |
|
|
|
6,375 |
|
|
|
3,680 |
|
Total operating expenses |
|
620,977 |
|
|
|
374,047 |
|
|
|
498,357 |
|
|
|
610,970 |
|
Operating loss |
$ |
(70,054 |
) |
|
$ |
(18,610 |
) |
|
$ |
(52,399 |
) |
|
$ |
(174,680 |
) |
(1)The 2022 segment financials have been recast to reflect the move of the IFP business to discontinued operations as well as to correct the accounting for gross versus net revenue recognition conclusion from certain value-based care arrangements and an error identified in the data to account for our risk adjustment factor. |
|||||||||||||||
Non-GAAP Financial Measures
We use the non-GAAP financial measures Adjusted EBITDA and Adjusted Operating Cost Ratio. We define Adjusted EBITDA as Net Loss excluding loss from discontinued operations, Interest Expense, Income Taxes, Depreciation and Amortization, adjusted for the impact of impairment of goodwill or intangible assets, acquisition and financing-related transaction costs, share-based compensation, changes in the fair value of contingent consideration, changes in the fair value of equity securities, contract termination and other exit costs and restructuring costs. We define Adjusted Operating Cost Ratio as Operating Cost Ration excluding share-based compensation. These non-GAAP measures have been presented in this quarterly Earnings Release as supplemental measures of financial performance that are not required by or presented in accordance with GAAP because we believe they assist management and investors in comparing our operating performance across reporting periods on a consistent basis by excluding and including items that we do not believe are indicative of our core operating performance. Management believes these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses Adjusted EBITDA and Adjusted Operating Cost Ratio to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.
Adjusted EBITDA is not a recognized term under GAAP and should not be considered as an alternative to Net Income (Loss) as a measure of financial performance or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a measure of free cash flow available for management’s discretionary use as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentation of Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
Adjusted Operating Cost Ratio is not a recognized term under GAAP and should not be considered as an alternative to Operating Cost Ratio as a measure of financial performance or any other performance measure derived in accordance with GAAP. The presentation of Adjusted Operating Cost Ratio has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentation of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
The following table provides a reconciliation of net loss to Adjusted EBITDA for the periods presented:
|
Three Months Ended
|
||||||
($ in thousands) |
|
2023 |
|
|
|
2022 |
|
Net loss |
$ |
(169,461 |
) |
|
$ |
(180,629 |
) |
Loss from discontinued operations (a) |
|
74,669 |
|
|
|
17,115 |
|
EBITDA adjustments from continuing operations: |
|
|
|
||||
Interest expense |
|
7,787 |
|
|
|
1,193 |
|
Income tax expense (benefit) |
|
1,259 |
|
|
|
3,242 |
|
Depreciation and amortization |
|
9,891 |
|
|
|
12,897 |
|
Transaction costs (b) |
|
1,849 |
|
|
|
852 |
|
Share-based compensation expense (c) |
|
33,320 |
|
|
|
32,921 |
|
Change in fair value of equity securities |
|
— |
|
|
|
40,968 |
|
Change in fair value of contingent consideration (d) |
|
(1,827 |
) |
|
|
— |
|
Termination and other exit costs (e) |
|
4,157 |
|
|
|
5,488 |
|
Restructuring costs (f) |
|
3,303 |
|
|
|
6,864 |
|
EBITDA adjustments from continuing operations |
$ |
59,739 |
|
|
$ |
104,425 |
|
Adjusted EBITDA |
$ |
(35,053 |
) |
|
$ |
(59,089 |
) |
| (a) | Beginning in the fourth quarter of 2022, Adjusted EBITDA excludes the impact of discontinued operations. The comparable period in 2022 has been recast to exclude these impacts. Represents losses associated with the Commercial business segment that we exited at the end of 2022. |
|
| (b) | Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees directly relating to financing initiatives. These costs can vary from period to period and impact comparability, and we do not believe such transaction costs reflect the ongoing performance of our business. |
|
| (c) | Represents non-cash compensation expense related to stock option and restricted stock unit award grants, which can vary from period to period based on a number of factors, including the timing, quantity and grant date fair value of the awards. |
|
| (d) | Represents the non-cash change in fair value of contingent consideration from business combinations, which is remeasured at fair value each reporting period. |
|
| (e) | Represents amounts paid for early termination of existing vendor contracts and, beginning in 2023, includes the impact of our MA legacy operations that we exited at the end of 2022. The adjustment in the comparable period in 2022 has been recast to include these impacts. |
|
| (f) | Restructuring costs represent severance costs as part of a workforce reduction and impairment of certain long-lived assets relating to our decision to exit the Commercial business for the 2023 plan year. |
The following table provides a reconciliation of Adjusted Operating Cost Ratio for the periods presented:
|
Three Months Ended
|
||
($ in thousands) |
2023 |
|
2022 |
Operating Cost Ratio |
|
|
|
Impact of Share-based compensation expense |
(4.4)% |
|
(5.4)% |
Adjusted Operating Cost Ratio |
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005350/en/
Investor Contact:
Stephen Hagan
IR@brighthealthgroup.com
Media Contact:
media@brighthealthgroup.com
Source: Bright Health Group, Inc.
